HRD Tests for Ovarian cancER
The study concerns patients with Invasive epithelial ovarian cancer, primary Fallopian tube carcinoma, ovarian-type peritoneal carcinoma, and with an indication of a first-line platinum-based chemotherapy. To determine HRD status, 2 separate tests will be performed in the study: 1. Giscar assay : developed by the sponsor 2. myChoice assay If one or two tests identifies a HRD status : a PARP inhibitor treatment may be initiated according to current recommendations
• Patient aged 18-year or more
• Histologically documented high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer
• Newly diagnosed advanced (International Federation of Gynecology and Obstetrics \[FIGO\] stage III or IV) ovarian carcinoma, candidate to a first line platinum-based chemotherapy
• Tumor tissue must be available for HRD analyses (FFPE tissue block) and
‣ Collected if possible during the initial surgery or the initial biopsy (before chemotherapy)
⁃ With sufficient tumour surface area (\> 25 mm²), with a final cellularity of at least 20%
• Patient affiliated to an appropriate social security system
• Patient signed consent form before any trial related activities